Loading...
AZD8186, a potent and selective inhibitor of PI3Kb/d, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
de Bono, JS Hansen, A Choudhury, AD Cook, Natalie Heath, EI Higano, C Linch, M Martin-Liberal, J Rathkopf, DE Wisinski, KB
de Bono, JS
Hansen, A
Choudhury, AD
Cook, Natalie
Heath, EI
Higano, C
Linch, M
Martin-Liberal, J
Rathkopf, DE
Wisinski, KB
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 114.63 KB
Keywords
Type
Meetings and Proceedings
Citation
de Bono JS, Hansen A, Choudhury AD, Cook N, Heath EI, Higano C, et al. 833P AZD8186, a potent and selective inhibitor of PI3K?/?, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 2018;29(suppl_8).